Meeting
2024 ASCO Genitourinary Cancers Symposium
Real-world outcomes of patients with operable renal cell carcinoma from the German translational cancer research consortium (DKTK) network.
Authors
Viktor Grünwald
Clinic for Internal Medicine (Tumor Research) and Department of Urology, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany
Viktor Grünwald , Christian Thomas , Maria De Santis , Christian Gratzke , Felix Chun , Rene Mager , Margitta Retz , Gunhild Von Amsberg , Philipp Ivanyi , Bolenz Christian , Hubert Kübler , Boris A. Hadaschik , Svenja Hahn , Ian Erhard , Bastian Reiter , Martin Lablans , Janne Vehreschild , Daniel Brucker , Daniel Maier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 394)
DOI
10.1200/JCO.2024.42.4_suppl.394
Abstract #
394
Poster Bd #
F18
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Predictive factors for recurrence and outcomes in T1a renal cell carcinoma: Analysis of the INMARC (International Marker Consortium for Renal Cancer) database.
First Author: Franklin Liu
Poster
2023 ASCO Genitourinary Cancers Symposium
Real world outcomes of patients with non-clear cell renal cell carcinoma: A single Asian centre experience.
First Author: Johan W.K. Chan
Poster
2016 Genitourinary Cancers Symposium
Prognostic utility of a multi-gene signature (the cell cycle proliferation score) in patients with renal cell carcinoma (RCC) after radical nephrectomy.
First Author: Todd Matthew Morgan
Poster
2024 ASCO Annual Meeting
Comparative analysis of pembrolizumab and cetuximab-based therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma: Real-world data.
First Author: Zahra Hamedi